atopic dermatitis

Thursday, Johnson & Johnson (NYSE:JNJ) agreed to acquire Proteologix Inc., a privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash, with the potential for an additional milestone payment. Proteologix...

Eli Lilly And Co (NYSE: LLY) outlined more data for its IL-13 inhibitor in atopic dermatitis (AD) patients. Lebrikizumab cleared up patients' skin at a statistically more significant rate than placebo. The data come from a Phase 3 study looking at lebrikizumab combined with...

VYNE Therapeutics Inc (NASDAQ: VYNE) announced positive efficacy results from the Phase 1b segment of Phase 1b/2a trial of FMX114 in mild-to-moderate atopic dermatitis (AD). Mean Atopic Dermatitis Severity Index (ADSI) scores for FMX114 and vehicle-treated lesions were 7.8 and 8.0,...

The FDA has accepted for Priority Review the supplemental marketing application for Dupixent (dupilumab) for children aged six months to 5 years with moderate-to-severe atopic dermatitis. Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceutical Inc (NASDAQ: REGN) are...

ASLAN Pharmaceuticals Ltd (NASDAQ: ASLN) has screened the first patient in its Phase 2b dose-ranging study of eblasakimab (ASLAN004) in adults with moderate-to-severe atopic dermatitis (AD).  Eblasakimab is a monoclonal antibody targeting the IL-13 receptor.  ASLAN expects...

The FDA has approved AbbVie Inc's (NYSE: ABBV) Rinvoq (upadacitinib) for atopic dermatitis in adults and children 12 years of age and older. The approval covers moderate to severe atopic dermatitis in patients whose disease did not respond to previous treatment, not well...

Hoth Therapeutics Inc (NASDAQ: HOTH) has begun enrollment and dosing for the second cohort in its Phase 1b trial of topical BioLexa to treat mild to moderate atopic dermatitis, also known as eczema.  What happened: The Company is conducting the trial in Australia, which includes mild...

Connect Biopharma Holdings Limited (NASDAQ: CNTB) has reported topline results from the Phase 2 trial of CBP-201 administered subcutaneously (SC) to adult patients with moderate-to-severe atopic dermatitis (AD). The data show that the trial met its primary efficacy endpoint, with...

AbbVie Inc (NYSE: ABBV) announced new analyses from the Phase 3 Rinvoq (upadacitinib) atopic dermatitis clinical trial program. Data were presented at the European Academy of Dermatology and Venereology (EADV) Virtual Congress. One analysis showed a greater proportion of patients...

The Japanese Ministry of Health, Labour, and Welfare (MHLW) has approved Pfizer Inc's (NYSE: PFE) Cibinqo (abrocitinib) for atopic dermatitis (AD). Related content: Benzinga's Full FDA Calendar. The approval covers adults and adolescents aged 12 years and older AD...

ASLAN Pharmaceuticals Ltd (NASDAQ: ASLN) has announced topline data from its Phase 1 study of ASLAN004 for moderate-to-severe atopic dermatitis (AD).  In March 2021, ASLAN announced interim data from three dose-escalation cohorts (200mg, 400mg, and 600mg). Today's...

The FDA has approved Incyte Corporation's (NASDAQ: INCY) Opzelura (ruxolitinib) cream for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD). Also Read: FDA Hits JAK inhibitors With Heart Safety, Cancer Warnings: All You Need To Know....

Pfizer Inc (NYSE: PFE) announced topline data from the JADE DARE Phase 3 trial comparing abrocitinib with Sanofi SA (NASDAQ: SNY) - Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Dupixent (dupilumab), in moderate to severe atopic dermatitis. The study met its...

A Phase 3 trial evaluating Dupixent (dupilumab) for treating children aged 6 months to 5 years with moderate-to-severe atopic dermatitis met its primary and secondary endpoints.  Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) are jointly...

Eli Lilly And Co's (NYSE: LLY) lebrikizumab ADvocate 1 and ADvocate 2 Phase 3 clinical trials met primary and all key secondary endpoints at Week 16.  Lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis (AD) in the two...